Literature DB >> 34346172

No pain, just gain: Painless, easy, and fast dried blood spot collection from fingertip and upper arm in doping control.

Sara Amalie Solheim1, Thomas Kamm Ringsted1, Nikolai B Nordsborg2, Yvette Dehnes3, Maren Christin Stillesby Levernaes3, Jakob Mørkeberg1.   

Abstract

This study aimed to determine and compare the perception, painfulness, and usability of the minimally invasive dried blood spot (DBS) collections from fingertip versus upper arm from different athlete populations: males and females representing sports dependent on hand/arm, sports less dependent on hand/arm and para-athletes. To accomplish this, 108 national level athletes from Denmark were recruited (♀ = 49, ♂ = 59, 25 ± 6 years; mean ± SD) and 11 Doping Control Officers (DCOs) collected manual fingerprick DBS (HemaSpot HF) and automated upper-arm DBS (Tasso-M20) from each athlete. Athletes and DCOs responded to questionnaires regarding the perception of sample collection procedures. On a 0-10 scale, the athletes reported a low pain score and a very good general experience for both sampling sites, but following upper-arm DBS collection, the associated pain was rated lower (-0.4 ± 1.6, p < 0.05), and the general experience rated better (+0.6 ± 2.3, p ≤ 0.001) than after the fingerprick DBS collection. The DCOs rated the general experience with the upper-arm DBS collection better (+1.6 ± 1.1, p ≤ 0.01) than the fingerprick DBS collection, partly because problems occurred more frequently during the DBS collection from the fingertip (28%) than from the upper arm (6%). In conclusion, it appears that DBS sampling is affiliated with minimal sensation of pain and is preferred by both DCOs and athletes, independent of gender and discipline, over conventional sample collection methods. Collection of DBS from the upper arm was preferred over fingerprick by both athletes and DCOs.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  anti-doping; dried blood spots (DBS); pain; questionnaire; sampling site

Mesh:

Year:  2021        PMID: 34346172     DOI: 10.1002/dta.3135

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  4 in total

1.  Accuracy and tolerability of self-sampling of capillary blood for analysis of inflammation and autoantibodies in rheumatoid arthritis patients-results from a randomized controlled trial.

Authors:  Johannes Knitza; Koray Tascilar; Nicolas Vuillerme; Ekaterina Eimer; Paul Matusewicz; Giulia Corte; Louis Schuster; Timothée Aubourg; Gerlinde Bendzuck; Marianne Korinth; Corinna Elling-Audersch; Arnd Kleyer; Sebastian Boeltz; Axel J Hueber; Gerhard Krönke; Georg Schett; David Simon
Journal:  Arthritis Res Ther       Date:  2022-05-25       Impact factor: 5.606

2.  Remote self-collection of capillary blood using upper arm devices for autoantibody analysis in patients with immune-mediated inflammatory rheumatic diseases.

Authors:  Joshua Zarbl; Ekaterina Eimer; Camilla Gigg; Gerlinde Bendzuck; Marianne Korinth; Corinna Elling-Audersch; Arnd Kleyer; David Simon; Sebastian Boeltz; Martin Krusche; Johanna Mucke; Felix Muehlensiepen; Nicolas Vuillerme; Gerhard Krönke; Georg Schett; Johannes Knitza
Journal:  RMD Open       Date:  2022-09

3.  Participant experiences using novel home-based blood collection device for viral load testing in the HIV cure trials with analytical treatment interruptions.

Authors:  Karine Dubé; Harsh Agarwal; William B Carter; Lynda Dee; Jeff Taylor; Christopher Roebuck; Beth Peterson; Hursch Patel; Samuel Ndukwe; Kenneth M Lynn; Linden Lalley-Chareczko; Emily Hiserodt; Sukyung Kim; Daniel Rosenbloom; Brad R Evans; Melanie Anderson; Daria J Hazuda; Kevin Bateman; Bonnie J Howell; Livio Azzoni; Karam Mounzer; Pablo Tebas; Luis J Montaner
Journal:  HIV Res Clin Pract       Date:  2022-08-02

4.  Optimizing detection of erythropoietin receptor agonists from dried blood spots for anti-doping application.

Authors:  Carmel E Heiland; Magnus Ericsson; Anton Pohanka; Lena Ekström; Alexandre Marchand
Journal:  Drug Test Anal       Date:  2022-03-30       Impact factor: 3.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.